Sulforaphane Inhibits Osteoclastogenesis by Inhibiting Nuclear Factor-κB

  • Kim, Soo-Jin (Department of Biological Sciences, and Immunomodulation Research Center, University of Ulsan) ;
  • Kang, So-Young (Department of Biological Sciences, and Immunomodulation Research Center, University of Ulsan) ;
  • Shin, Hyun-Hee (Department of Biological Sciences, and Immunomodulation Research Center, University of Ulsan) ;
  • Choi, Hye-Seon (Department of Biological Sciences, and Immunomodulation Research Center, University of Ulsan)
  • Received : 2005.07.05
  • Accepted : 2005.08.26
  • Published : 2005.12.31


We show that sulforaphane inhibits osteoclastogenesis in the presence of macrophage colony-stimulating factor (M-CSF) and receptor for activation of nuclear factor-${\kappa}B$ ligand (RANKL) in osteoclast (OC) precursors. Sulforaphane, an aliphatic isothiocyanate, is a known cancer chemo-preventative agent with anti-oxidative properties. Nuclear factor-${\kappa}B$ (NF-${\kappa}B$) is a critical transcription factor in RANKL-induced osteoclastogenesis, and electrophoretic mobility shift assays (EMSAs) and assay of NF-${\kappa}B$-mediated secreted alkaline phosphatase (SEAP) revealed that sulforaphane selectively inhibited NF-${\kappa}B$ activation induced by RANKL. Inhibition may involve interaction of sulforaphane with thiol groups, since it was prevented by reducing agents.


Bone Marrow-derived Macrophages;NF-${\kappa}B$;Osteoclastogenesis;RANKL;Sulforaphane;Thiol


Supported by : KOSEF


  1. Arai, F., Miyamoto, T., Ohnetda, O., Inada, T., Sudo, T., et al. (1999) Commitment and differentiation of osteoclast precursor cells by the sequential expression of c-Fms and receptor activator of nuclear factor ${\kappa}B$ (RANK) receptor. J. Exp. Med. 190, 1741-1746
  2. Franzoso, G., Carlson, L., Xing, L., Poljak, L., Shores, E. W., et al. (1997) Requirement for NF-${\kappa}B$ in osteoclast and B-cell development. Genes Dev. 11, 3482-3496
  3. Rassi, C. M., Lieberherr, M., Chaumaz, G., Pointillart, A., and Cournot, G. (2002) Down-regulation of osteoclast differentiation by daidzein via caspase 3. J. Bone Miner. Res. 17, 630-638
  4. Roodman, G. D. (1996) Advances in bone biology: the osteoclast. Endocr. Rev. 17, 308-332
  5. Schreck, R., Meier, B., Mannel, D. N., Droge, W., and Baeuerle, P. A. (1992) Dithiocarbamates as potent inhibitors of nuclear factor ${\kappa}B$ activation in intact cells. J. Exp. Med. 175, 1181-1194
  6. Shevdo, N. K., Bendixen, A. C., Dienger, K. M., and Pike, J. W. (2000) Estrogens suppress RANK ligand-induced osteoclast differentiation via stromal cell independent mechanism involving c-Jun repression. Proc. Natl. Acad. Sci. USA 97, 7829-7834
  7. Yamagashi, T., Otsuka, E., and Hagawara, H. (2001) Reciprocal control of expression of mRNAs for osteoclast differentiation factor and OPG in osteogenic stromal cells by genistein: evidence for the involvement of topoisomease II in osteoclastogenesis. Endocrinology 142, 3632-3637
  8. Zhang, Y. (2000) Role of glutathione in the accumulation of anticarcinogenic isothiocyanates and their glutathione conjugates by murine hepatoma cells. Carcinogenesis 21, 1175-1182
  9. Iotsova, V., Caamano, J., Loy, J., Yang, Y., Lewin, A., et al. (1997) Osteopetrosis in mice lacking NF-${\kappa}B1$ and NF-${\kappa}B2$. Nat. Med. 3, 1285-1289
  10. Morabito, N., Crisafulli, A., Vergara, C., Gaudio, A., Lasco, A., et al. (2002) Effects of genistein and hormone replacement therapy on bone loss in early postmenopausal woman: a randomized double-blind placebo-controlled study. J. Bone Miner. Res. 17, 1904-1912
  11. Jimi, E., Nakamura, I., Amano, H., Taguchi, Y., Tsurukai, T., et al. (1996) Osteoclast function is activated by osteoblastic cells through a mechanism involving cell-to-cell contact. Endocrinology 137, 2187-2190
  12. Zhang, Y., Talalay, P., Cho, C. G., and Posner, G. H. (1992) A major inducer of anticarcinogenic protective enzymes from broccoli: isolation and elucidation of structure. Proc. Natl. Acad. Sci. USA 89, 2399-2403
  13. Schmidt, T. J., Lyb, G., Pajl, H. L., and Merfor, I. (1999) Helenanolide type sesquiterpene lactones. Part 5: The role of glutathione addition under physiological conditions. Bioorg. Med. Chem. 7, 2849-2855
  14. Nakagawa, H., Wachi, M., Woo, J. T., Kato, M., Kasai, S., et al. (2002) Fenton reaction is primarily involved in a mechanism of (-)-epigallocatechin-3-gallate to induce osteoclastic cell death. Biochem. Biophys. Res. Commun. 292, 94-101
  15. Baldwin, A. S. (1996) The NF-kappa B and I kappa B proteins: new discoveries and insights. Ann. Rev. Immunol. 14, 649-683
  16. Fahey, J. W., Haristoy, X., Dolan, P. M., Kensler, T. W., Scholtus, I., et al. (2002) Sulforaphane inhibits extracellular, intracellular, and antibiotic-resistant strains of Helicobacter pylori and prevents benzo[a]pyrene-induced stomach tumors. Proc. Natl. Acad. Sci. USA 99, 7610-7615
  17. Suda, T., Takahashi, N., Udagawa, N., Jimi, E., Gillespie, M. T., et al. (1999) Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr. Rev. 20, 345-357
  18. Hiramoto, M., Shimizu, N., Sugimoto, K., Tang, J., Kawakami, Y., et al. (1998) Nuclear targeted suppression of NF-${\kappa}B$ activity by the novel quinone derivative E3330. J. Immunol. 160, 810-819
  19. Hecht, S. S. (1999) Chemoprevention of cancer by isothiocyanates, modifiers of carcinogen metabolism. J. Nutr. 129, 768S-774S
  20. Tsai, S. H., Lin-Shiau, S. Y., and Lin, J. K. (1999) Suppression of nitric oxide synthase and the down-regulation of the activation of NFkappaB in macrophages by resveratrol. Br. J. Pharmacol. 126, 673-680
  21. Gerhauser, C., You, M., Liu, J., Moriarty, R. M., Hawthorne, M., et al. (1997) Cancer chemopreventive potential of sulforamate, a novel analogue of sulforaphane that induces phase 2 drugmetabolizing enzymes. Cancer Res. 57, 272-278
  22. Yao, K. S., Hageboutros, A., Ford, P., and O-Dwyer, P. J. (1997) Involvement of activator protein-1 and nuclear factor-kappaB transcription factors in the control of the DT-diaphorase expression induced by mitomycin C treatment. Mol. Pharmcol. 51, 422-430
  23. Lee, Z. H. and Kim, H. H. (2003) Signal transduction by receptor activator of nuclear factor kappa B in osteoclasts. Biochem. Biophys. Res. Commun. 305, 211-214
  24. Wang, B. and Williamson, G. (1996) Transcriptional regulation of the human NAD(P)H:quinone oxidoreductase (NQO1) gene by monofunctional inducers. Biochim. Biophys. Acta 1307, 104-110
  25. Sen, C. K. (2000) Cellular thiols and redox-regulated signal transduction. Curr. Top Cell Regul. 36, 1-30
  26. Zhang, Y., Kensler, T. W., Cho, C. G., Posner, G. H., and Talalay, P. (1994) Anticarcinogenic activities of sulforaphane and structurally related synthetic norbornyl isothiocyanates. Proc. Natl. Acad. Sci. USA 91, 3147-3150
  27. Heiss, E., Herhaus, C., Klimo, K., Bartsch, H., and Gerhauser, C. (2001) Nuclear factor-${\kappa}B$ is a molecular target for sulforaphane- mediated anti-inflammatory mechanism. J. Biol. Chem. 276, 32008-32015
  28. New, S. A., Robins, S. P., Campbell, M. K., Martin, J. C., Garton, M. J., et al. (2000) Dietary influences on bone mass and bone metabolism: further evidences on a positive link between fruit and vegetable consumption and bone health? Am. J. Clin. Nutr. 71, 142-151
  29. Umezawa, K. and Chaicharoenpong, C. (2002) Molechlar design and biological activities of NF-kappa B inhibitors. Mol. Cells 14, 163-167
  30. Wattel, A., Kamel, S., Prouillet, C., Petit, J. P., lorget, F., et al. (2004) Flavonoid quercetin decreasesosteoclastic differentiation induced by RANKL via a mechanism involving NF-${\kappa}B$ and AP-1. J. Cell Biochem. 92, 285-295
  31. Gao, X., Dinkova-Kostova, A. T., and Talalay, P. (2001) Powerful and prolonged protection of human retinal pigment epithelial cells, keratinocytes, and mouse leukemia cells against oxidative damage: the indirect antioxidant effects of sulforaphane. Proc. Natl. Acad. Sci. USA 98, 15221-15226